Search In this Thesis
   Search In this Thesis  
العنوان
Clinical Utility of Third Trimester’s Endocan-1 Levels in Pregnant Women with Diabetes Mellitus/
المؤلف
Farid,Mai Mohamed Mohamed .
هيئة الاعداد
باحث / مي محمد محمد فريد الجندي
مشرف / منــــى محمــــد زكــــي
مشرف / عــادل أحمـد العزب الجد
مشرف / دعــاء مصطفــى عــوض
تاريخ النشر
2017.
عدد الصفحات
143.p;
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب (متفرقات)
تاريخ الإجازة
1/7/2017
مكان الإجازة
جامعة عين شمس - كلية الطب - Clinical Pathology
الفهرس
Only 14 pages are availabe for public view

from 143

from 143

Abstract

Diabetes mellitus (DM) is considered one of the most common metabolic complications occurring in pregnancy. Both, type 1 and type 2 may be diagnosed before pregnancy and thus called pregestational diabetes. On the other hand, if diabetes is diagnosed for the first time during pregnancy, it is called gestational diabetes. In 2012, Schneider and his co-workers stated that gestational diabetes mellitus (GDM) accounts for about 90% of cases of DM in pregnancy worldwide. They added that pre-existing diabetes accounts for 10 % of such cases. Kim et al. added that first degree relatives with diabetes, increased weight and decreased physical activity were well established risk factors for developing GDM. Endocan-1, previously called endothelial cell specific molecule-1, is a soluble proteoglycan of 50 kDa. Aim: Assessment of a probable relationship between third trimester’s serum endocan-1 levels and glycemic control as well as diabetes-related complications in pregnant women with diabetes. The aim of the present study was to assess serum endocan in a group of pregnant females with diabetes and the probable relationship between third trimester’s serum endocan-1 levels and glycemic control monitored by HbA1c and OGTT as well as diabetes-related complications in pregnant women with diabetes. Based on these facts, this study was conducted on eighty pregnant females, classified into three groups: twenty pregnant females with pre-existing DM (group Ia), forty pregnant females with GDM (group Ib) and twenty five normal controls (group II). Statistical analysis for results of our study revealed a highly significant rise in serum endocan-1 levels in pregnant diabetic females (group I) either with pre-existing DM or newly developed GDM when compared to our non diabetic control group. Meanwhile, there is no statistical significant differernce between serum endocan-1 level between pregnant females with pre-existing DM and GDM.